Dialysis patients may get stronger vaccine shield with old drug

NCT ID NCT07587801

First seen May 18, 2026 · Last updated May 18, 2026

Summary

This study tests whether a short course of low-dose Sirolimus, a drug usually used in transplant patients, can boost the immune response to flu and RSV vaccines in people over 60 who are on hemodialysis. About 60 participants will receive the drug or a placebo before vaccination. The goal is to see if this approach improves long-term immune memory and protection.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OLDER ADULTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Princess Alexandra Hospital

    Woolloongabba, Queensland, 4102, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Royal Adelaide Hospital

    Adelaide, South Australia, 5000, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Royal Prince Alfred Hospital

    Camperdown, New South Wales, 2050, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.